Segui
Gustavo Aroca-Martinez
Gustavo Aroca-Martinez
Altri nomiAroca-Martinez,Gustavo, Aroca.gustavo, Gustavo Aroca
Universidad Simón Bolívar, Barranquilla, Colombia.
Email verificata su unisimon.edu.co - Home page
Titolo
Citata da
Citata da
Anno
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
J Sadoff, G Gray, A Vandebosch, V Cárdenas, G Shukarev, B Grinsztejn, ...
The new england journal o f medicine 384, 2187-2201, 2021
27302021
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
P López-Jaramillo, E Barbosa, DI Molina, R Sanchez, M Diaz, ...
The Lancet, 2019
26782019
Rivaroxaban with or without aspirin in stable cardiovascular disease
JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ...
New England Journal of Medicine 377 (14), 1319-1330, 2017
26112017
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
New England Journal Medicine 383 (23), 2219-229, 2020
20632020
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
J Rosenstock, J (Rosenstock, V Perkovic, V (Perkovic, ...
JAMA 321 (1), 61-67, 2019
1203*2019
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
B Pitt, G Filippatos, R Agarwal, S Anker, G Bakris, P Rossing, A Joseph, ...
the New England Journal of Medicine 385 (4), 2252-2263, 2021
11902021
Cholesterol lowering in intermediate-risk persons without cardiovascular disease
S Yusuf, J Bosch, G Dagenais, J Zhu, D Xavier, L Liu, P Pais, ...
New England Journal of Medicine 374 (21), 2021-2031, 2016
10792016
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
C Anand,S,Bosch,J,Eikelboon,J
THE LANCET 391 (1017), 219-229, 2018
9982018
Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
EM Lonn, J Bosch, P López-Jaramillo, J Zhu, L Liu, P Pais, R Diaz, ...
New England Journal of Medicine 374 (21), 2009-2020, 2016
8322016
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...
The Lancet 394 (10193), 131-138, 2019
6162019
Blood-pressure and cholesterol lowering in persons without cardiovascular disease
S Yusuf, E Lonn, P Pais, J Bosch, P Lopez-Jaramillo, J Zhu, D Xavier, ...
New England Journal of Medicine 374 (21), 2032-2043, 2016
5082016
Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Gastroenterology, 2019
4842019
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
SJ Connolly, JW Eikelboom, J Bosch, G Dagenais, L Dyal, F Lanas, ...
LANCET 20 (391), 205-218, 2018
4122018
May Measurement Month 2017: an analysis of blood pressure screening results worldwide
THE LANCET GLOBAL HEALTH 6 (7), 736-743, 2018
3932018
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, doubleblind, placebo-controlled trial
RA Furie, G Aroca, MD Cascino, JP Garg, BH Rovin, A Alvarez, ...
Annals of the Rheumatic Diseases 80 (1), 2021
3022021
May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension.
European heart journal 40 (25), 2006-2017, 2019
2822019
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
G Filippatos, Stefan D. Anker, R Agarwal, B Pitt, LM Ruilope, P Rossing, ...
CIRCULATION 143 (6), 540-552, 2021
2642021
May Measurement Month 2019 The Global Blood Pressure Screening Campaign of the International Society of Hypertension
T Beaney, A Schutte, G Stergiou, C Borghi, als. et
HYPERTENSION 76 (2), 333-341, 2020
2592020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
The Lancet Neurology 19 (7), 582-590, 2020
2192020
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies
Canadian Journal of Cardiology 33 (8), 1027-1035, 2017
2122017
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20